A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma

Trial Profile

A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2017

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CALM
  • Sponsors Viralytics
  • Most Recent Events

    • 07 Jun 2016 Combined results of parent and extension study assessing the dynamics of tumor response (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2016 Results (extension study) assessing the impact of CVA21 on immune cell infiltrates and immune checkpoint molecules within treated lesions presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 09 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top